Goldman Sachs
ACHV icon

Goldman Sachs’s Achieve Life Sciences ACHV Stock Holding History

Goldman Sachs’s Portfolio ACHV Stock Details ACHV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$268K Sell
40,976
-111,976
-73% -$534K ﹤0.01% 6054
2026
Q1 		$450K Sell
152,952
-297,976
-66% -$1.32M ﹤0.01% 5662
2025
Q4 		$2.24M Buy
450,928
+227,095
+101% +$990K ﹤0.01% 4485
2025
Q3 		$705K Buy
223,833
+163,918
+274% +$450K ﹤0.01% 5292
2025
Q2 		$135K Sell
59,915
-50,431
-46% -$144K ﹤0.01% 5758
2025
Q1 		$295K Sell
110,346
-40,829
-27% -$127K ﹤0.01% 5468
2024
Q4 		$532K Sell
151,175
-83,690
-36% -$379K ﹤0.01% 5216
2024
Q3 		$1.11M Buy
234,865
+200,327
+580% +$915K ﹤0.01% 4562
2024
Q2 		$162K Buy
34,538
+12,320
+55% +$59.4K ﹤0.01% 5314
2024
Q1 		$101K Buy
+22,218
New +$98.6K ﹤0.01% 5246
2021
Q1 		– Sell
-10,816
Closed -$88K – 6038
2020
Q4 		$88K Buy
+10,816
New +$91.6K ﹤0.01% 5310
2020
Q1 		– Sell
-638
Closed -$7K – 5182
2019
Q4 		$7K Buy
+638
New +$13.7K ﹤0.01% 5180
2017
Q3 		– Sell
-8
Closed -$6K – 6631
2017
Q2 		$6K Hold
8
– – ﹤0.01% 6681
2017
Q1 		$8K Hold
8
– – ﹤0.01% 6628
2016
Q4 		$9K Sell
8
-1
-11% -$988 ﹤0.01% 6769
2016
Q3 		$10K Sell
9
-2
-18% -$3.19K ﹤0.01% 6871
2016
Q2 		$24K Sell
11
-2
-15% -$4.18K ﹤0.01% 6656
2016
Q1 		$20K Sell
13
-2
-13% -$3.26K ﹤0.01% 6743
2015
Q4 		$40K Buy
15
+2
+15% +$8.45K ﹤0.01% 6642
2015
Q3 		$63K Sell
13
-3
-19% -$18.1K ﹤0.01% 6696
2015
Q2 		$79K Buy
16
+2
+14% +$9.92K ﹤0.01% 6715
2015
Q1 		$66K Sell
14
-21
-60% -$103K ﹤0.01% 6603
2014
Q4 		$174K Sell
35
-19
-35% -$92.9K ﹤0.01% 6266
2014
Q3 		$319K Buy
54
+46
+575% +$320K ﹤0.01% 5702
2014
Q2 		$67K Buy
8
+5
+167% +$61.4K ﹤0.01% 6681
2014
Q1 		$76K Buy
+3
New +$73.7K ﹤0.01% 6475

Other funds holding ACHV

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Goldman Sachs's ACHV Position: Q2 2026 in Review

Goldman Sachs reduced its Achieve Life Sciences (ACHV) stake by 73% in Q2 2026, selling an estimated $534K and leaving 40,976 shares worth $268K. The position accounts for ﹤0.01% of the portfolio, ranked #6054.

Goldman Sachs first reported a position in ACHV in Q1 2014 and has held it in 26 quarters since. The position peaked at $2.24M in Q4 2025. 111 funds tracked by Wall St. Rank hold ACHV as of Q2 2026.

  • Goldman Sachs held 40,976 shares of Achieve Life Sciences worth $268K as of Q2 2026.
  • Goldman Sachs sold 111,976 Achieve Life Sciences shares in Q2 2026, an estimated $534K.
  • Achieve Life Sciences made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #6054 holding.
  • Goldman Sachs first reported a position in Achieve Life Sciences in Q1 2014 and has held it in 26 quarters since.
  • Goldman Sachs's Achieve Life Sciences position peaked at $2.24M in Q4 2025.
  • 111 funds tracked by Wall St. Rank held Achieve Life Sciences as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.